Document Detail


Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.
MedLine Citation:
PMID:  18027874     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients with advanced cirrhosis and ascites are characterized by circulatory dysfunction with splanchnic vasodilatation and renal vasoconstriction, which often lead to ascites. The vasoconstrictor terlipressin improves renal function in hepatorenal syndrome (HRS). The aim of this study was to evaluate if terlipressin also improves renal function in patients with ascites without HRS. Twenty-three patients with cirrhosis participated; 15 with nonrefractory ascites were randomized to either terlipressin (N group, n = 11) or a placebo (P group, n = 4), and 8 had refractory ascites and received terlipressin (R group). The glomerular filtration rate (GFR), sodium clearance (C(Na)), lithium clearance (C(Li)), osmolal clearance (C(Osm)), and urine sodium concentration (U(Na)) were assessed before and after the injection of 2 mg of terlipressin or the placebo. GFR increased in the N group (69 +/- 19 versus 92 +/- 25 mL/min, P < 0.005) and in the R group (31 +/- 19 versus 41 +/- 31 mL/min, P < 0.05) after terlipressin. In the N group, terlipressin induced an increase in C(Na) (0.89 +/- 0.21 versus 1.52 +/- 1.45 mL/min, P < 0.05), C(Li) (17.3 +/- 8.9 versus 21.5 +/- 11.6 mL/min, P < 0.05), and C(Osm) (2.10 +/- 0.81 versus 3.06 +/- 2.0 mL/min, P < 0.05). In the R group, terlipressin induced an increase in C(Na) (0.11 +/- 0.18 versus 0.35 +/- 0.40 mL/min, P < 0.05) and C(Li) (5.5 +/- 4.2 versus 9.5 +/- 8.55 mL/min, P < 0.05). U(Na) increased in both groups after terlipressin (P < 0.005). Plasma norepinephrine (P < 0.05) and renin (P < 0.05) decreased after terlipressin. All parameters remained unchanged after the placebo. Conclusion: The vasopressin 1 receptor agonist terlipressin improves renal function and induces natriuresis in patients with cirrhosis and ascites without HRS. Vasoconstrictors may represent a novel future treatment modality for these patients.
Authors:
Aleksander Krag; Søren Møller; Jens H Henriksen; Niels-Henrik Holstein-Rathlou; Fin Stolze Larsen; Flemming Bendtsen
Related Documents :
1887934 - Interstitial adenosine concentration during norepinephrine infusion in isolated guinea ...
2941634 - Role of increased glomerular filtration rate in atrial natriuretic factor-induced natri...
966374 - Plasma catecholamine levels in the coronary sinus, aorta and femoral vein of subjects u...
2266754 - The effect of training on the norepinephrine response at rest and during exercise in 5 ...
19543214 - Influences of normobaric hypoxia training on physical fitness and metabolic risk marker...
11542354 - Effects of physiological salt water injection after 20 days of head down tilt bed rest ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  46     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-12-06     Completed Date:  2008-01-10     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1863-71     Citation Subset:  IM    
Affiliation:
Department of Gastroenterology, Hvidovre Hospital, Denmark. aleksander.krag@hvh.regionh.dk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Ascites / etiology
Double-Blind Method
Female
Glomerular Filtration Rate / drug effects
Hepatorenal Syndrome
Humans
Kidney / blood supply,  drug effects,  physiopathology*
Kidney Diseases / drug therapy*,  etiology
Liver Cirrhosis, Alcoholic / complications*
Lypressin / analogs & derivatives*,  pharmacology,  therapeutic use
Male
Middle Aged
Receptors, Vasopressin / drug effects
Recovery of Function
Vasoconstrictor Agents / pharmacology,  therapeutic use*
Chemical
Reg. No./Substance:
0/Receptors, Vasopressin; 0/Vasoconstrictor Agents; 14636-12-5/terlipressin; 50-57-7/Lypressin
Comments/Corrections
Comment In:
Hepatology. 2007 Dec;46(6):1685-7   [PMID:  18046716 ]
Hepatology. 2008 Aug;48(2):686   [PMID:  18666233 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genetic predictors of long-term toxicities after radiation therapy for breast cancer.
Next Document:  Dendritic cells, the liver, and transplantation.